The clinical trials are running to plan and IHL-42X could be the first drug for OSA in a $5 billion per year market. IHL has $40m in the bank and big Pharma has a tonne of cash on the sidelines to deploy.
If IHL was a private company we’d all be sleeping soundly because the company has never been in better shape and the upside looks enormous and very real.
Unless you understand how to approach a volatile market you’ll just end up making an emotional decision over price.
My thoughts are, don’t be a screen junky. If the investment proposition hasn’t changed (personally I think that’s the case, in fact the story keeps getting better) then sometimes it’s better to just turn your computer off.
IHL Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held